Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00267553 · ClinicalTrials.gov registry record · Phase 3
Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer
A Phase 3 study, sponsored by Intarcia Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 200
- Enrollment target
NCT00267553 is a Phase 3 study that was terminated before completion, run by Intarcia Therapeutics. The registered enrollment target is 200 participants.
The verdict
NCT00267553, a Phase 3 study, was terminated before completion, sponsored by Intarcia Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 200 participants
- Enrollment target
Study Summary
Protocol 777-CLP-32 is the treatment and survival continuation protocol of Biomed 777-CLP-29, and will continue to compare combined hormonal therapy using the experimental aromatase inhibitor (AI) atamestane combined with the FDA-approved anti-estrogen toremifene (Fareston®), to the single agent FDA-approved aromatase inhibitor letrozole (Femara®) for the treatment of advanced breast cancer. The purpose of this study is to determine whether maximal estrogen suppression achieved via the combination of atamestane, plus toremifene (Fareston®), is more effective than letrozole (Femara®) in delaying the growth of breast cancer.
Interventions
- DRUG letrozole
- DRUG toremifene
- DRUG Atamestane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2005-11 |
| Est. Completion | 2006-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00267553
The ClinicalTrials.gov registry entry for NCT00267553 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Intarcia Therapeutics, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which letrozole is the first listed.
NCT00267553 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00267553 about?
NCT00267553 is a clinical study titled "Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer". Protocol 777-CLP-32 is the treatment and survival continuation protocol of Biomed 777-CLP-29, and will continue to compare combined hormonal therapy using the experimental aromatase inhibitor (AI) atamestane combined with the FDA-approved anti-estrogen toremifene (Fareston®), to the single agent FDA...
What is the current status of trial NCT00267553?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 200 participants. The study started on 2005-11. Estimated completion is 2006-06.
What interventions are being tested in trial NCT00267553?
The interventions under investigation include: letrozole (DRUG), toremifene (DRUG), Atamestane (DRUG).
Who is sponsoring clinical trial NCT00267553?
This trial is sponsored by Intarcia Therapeutics, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.